Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippia finds jobs where you're a top candidate and applies on your behalf.
Express Scripts Holding's peak revenue was $104.1B in 2013. The peak quarterly revenue was $27.5B in 2012(q2).
Express Scripts Holding's revenue increased from $46.1b in 2011 to $100.1B currently. That's a 116.93% change in annual revenue.
| Fiscal year / year | Express Scripts Holding revenue |
|---|---|
| 2011 | $46.1B |
| 2012 | $93.7B |
| 2013 | $104.1B |
| 2014 | $100.9B |
| 2015 | $101.8B |
| 2016 | $100.3B |
| 2017 | $100.1B |
How accurately did Express Scripts Holding's revenue projections match actual performance?
Express Scripts Holding saw the greatest revenue growth in 2012, when revenue increased by 103.16%.
Express Scripts Holding had the lowest revenue growth in 2014, when revenue changed by -3.09%.
| Year | Express Scripts Holding growth |
|---|---|
| 2012 | 103%↑ |
| 2013 | 11%↑ |
| 2014 | -3%↓ |
| 2015 | 1%↑ |
| 2016 | -1%↓ |
| 2017 | -0%↓ |
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2011 | - | - | - | $12.1B |
| 2012 | $12.1B | $27.5B | $26.8B | $27.4B |
| 2013 | $26.0B | $26.4B | $25.9B | $25.8B |
| 2014 | $23.7B | $25.1B | $25.8B | $26.3B |
| 2015 | $24.9B | $25.5B | $25.2B | $26.2B |
| 2016 | $24.8B | $25.2B | $25.4B | $24.9B |
| 2017 | $24.7B | $25.3B | $24.7B | $25.4B |
| 2018 | $24.8B | $25.6B | $25.6B | - |
Do you work at Express Scripts Holding?
Is Express Scripts Holding transparent about its revenue structure?
| CEO | Tim Wentworth |
| Industry | Commercial & Professional Services |
| Company Type | Public |
| Employees Number | 26,600 |
| Date Founded | 1986 |
| Headquarters | Saint Louis, Missouri |
| Number of Locations | 4 |
| Revenue | $100.1B |
| Net Income | $4,517,400,000 |
| Gross Proft | $8.8B (2017) |
| PE Ratio | 7.97 |
| Tax Rate | 0.1% |
| Market Capitalization | $36.0B |
| Total Assets | $54,255,800,000 |
| Ticker | ESRX |
Express Scripts Holding's top competitor, UnitedHealth Group, earned an annual revenue of $400.3B.
Express Scripts Holding's smallest competitor is Seagen with revenue of $2.0B last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| UnitedHealth Group | $51,208 | $400.3B | 300,000 | 8,364 |
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 814 |
| Cardinal Health | $48,123 | $226.8B | 48,000 | 6,408 |
| Community Health Systems | $54,553 | $12.6B | 120,000 | 4,889 |
| McKesson | $51,976 | $309.0B | 80,000 | 501 |
| Centene | $58,575 | $163.1B | 65,000 | 472 |
| Owens & Minor | $38,357 | $10.7B | 17,900 | 904 |
| Johnson & Johnson | $76,686 | $88.8B | 134,500 | 1,585 |
| Medco Tool | $49,189 | $70.1B | 24,000 | - |
| Coventry Health Care | $47,768 | $14.1B | 14,400 | 1 |
Zippia gives an in-depth look into the details of Express Scripts Holding, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Express Scripts Holding. The employee data is based on information from people who have self-reported their past or current employments at Express Scripts Holding. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Express Scripts Holding. The data presented on this page does not represent the view of Express Scripts Holding and its employees or that of Zippia.
Express Scripts Holding may also be known as or be related to EXPRESS SCRIPTS INC, Express Scripts, Express Scripts Holding and Express Scripts Holding Company.